Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA3 | P07451 | 1/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
| ▸ | CA6 | P23280 | 1/20 | 0.45 |
| ▸ | CA5A | P35218 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18732384 | 0.93 | CHRM2 (0.42) | PIK3CDLMNACA12CA1CA2 | |
| SCHEMBL18721301 | 0.86 | LMNA (0.42) | PIK3CDLMNACA12CA1CA2 | |
| SCHEMBL13377536 | 0.84 | LMNA (0.49) | PIK3CDLMNACA12CA1CA2 | |
| SCHEMBL13178521 | 0.84 | LMNA (0.49) | PIK3CDLMNACA12CA1CA2 | |
| SCHEMBL13175198 | 0.83 | LMNA (0.54) | PIK3CDLMNACA12CA1CA2 | |
| SCHEMBL13541869 | 0.81 | PIK3CD (0.50) | PIK3CDLMNACA12CA1CA2 | |
| SCHEMBL23951725 | 0.80 | LMNA (0.42) | PIK3CDLMNACA12CA1CA2 | |
| SCHEMBL18687481 | 0.80 | LMNA (0.47) | PIK3CDLMNACA12CA1CA2 | |
| SCHEMBL13431629 | 0.80 | TOP2A (0.38) | PIK3CDLMNAAPOBEC3ARECQLAPOBEC3G | |
| SCHEMBL19380676 | 0.80 | CHRM2 (0.40) | PIK3CDLMNACA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024015971-A2 | MULTILAYER BATTERY SEPARATOR COMPRISING A MICROPOROUS POLYMER LAYER | SEPION TECHNOLOGIES, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| US-11859315-B1 | Fabrication of multifunctional BN fine fibers by force spinning method | UNITED STATES OF AMERICA AS REPRESENTED BY THE ADMINISTRATOR OF NATIONAL AERONAUTICS AND SPACE ADMINISTRATION (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230366818-A1 | ANALYSIS METHOD INVOLVING MEASUREMENT BASED ON POLARIZATION ANISOTROPY, TEST KIT, AND TEST REAGENT | CANON KABUSHIKI KAISHA (JP) | 2023-11-16 | — | — | US | disclosed |
| WO-2023183900-A1 | TYK2 INHIBITOR FORMULATIONS AND METHODS OF MAKING THE SAME | NIMBUS LAKSHMI, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| US-20230265087-A1 | SMALL MOLECULE ACTIVATORS OF TIE-2 | EyePoint, Inc. | 2023-08-24 | — | — | US | disclosed |
| US-11692325-B2 | Compositions for use in geosynthetic liners | IMERTECH SAS (FR) | 2023-07-04 | — | — | US | disclosed |
| US-20230155246-A1 | SEPARATOR FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY COMPRISING SAME | LG ENERGY SOLUTION, LTD. (KR) | 2023-05-18 | — | — | US | disclosed |
| EP-4138201-A1 | SEPARATOR FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY COMPRISING SAME | LG Energy Solution, Ltd. (KR) | 2023-02-22 | — | — | EP | disclosed |
| US-20230041546-A1 | SUPERFICIALLY POROUS MATERIALS COMPRISING A SUBSTANTIALLY NONPOROUS HYBRID CORE HAVING NARROW PARTICLE SIZE DISTRIBUTION | WATERS TECHNOLOGIES CORPORATION (US) | 2023-02-09 | — | — | US | disclosed |
| EP-4101297-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | Aerpio Pharmaceuticals, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| US-7731844-B2 | Porous materials for solid phase extraction and chromatography and processes for preparation and use thereof | WATERS TECHNOLOGIES CORPORATION (US) | 2010-06-08 | — | — | US | disclosed |
| US-20100009132-A1 | SELF-SEGREGATING MULTILAYER IMAGING STACK WITH BUILT-IN ANTIREFLECTIVE PROPERTIES | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2010-01-14 | — | — | US | disclosed |
| EP-2123639-A1 | PROCESS FOR PRODUCTION OF 2,3'-BIPYRIDYL-6'-ONE | Fujifilm Finechemicals Co. Ltd. (JP) | 2009-11-25 | — | — | EP | disclosed |
| US-20090139323-A1 | NOVEL ION EXCHANGE POROUS RESINS FOR SOLID PHASE EXTRACTION AND CHROMATOGRAPHY | WATERS INVESTMENTS LIMITED (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090139323-A1 | NOVEL ION EXCHANGE POROUS RESINS FOR SOLID PHASE EXTRACTION AND CHROMATOGRAPHY | WATERS INVESTMENTS LIMITED (US) | 2009-06-04 | — | — | US | disclosed |
| US-7442299-B2 | Ion exchange porous resins for solid phase extraction and chromatography | WATERS INVESTMENTS LIMITED (US) | 2008-10-28 | — | — | US | disclosed |
| WO-2008073424-A9 | ANSAMYCIN FORMULATIONS AND METHODS OF USE THEREOF | INFINITY DISCOVERY INC (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008073424-A2 | ANSAMYCIN FORMULATIONS AND METHODS OF USE THEREOF | INFINITY DISCOVERY, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| US-20070205156-A1 | Novel ion exchange porous resins for solid phase extraction and chromatography | WATERS INVESTMENTS LIMITED (US) | 2007-09-06 | — | — | US | disclosed |
| US-7232520-B1 | Ion exchange porous resins for solid phase extraction and chromatography | WATERS INVESTMENTS LIMITED (US) | 2007-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265087-A1 | SMALL MOLECULE ACTIVATORS OF TIE-2 | TIE1, TEK, KDR | PIK3CD 738/4885LMNA 4269/4885CA12 4651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.